熱門資訊> 正文
Jazz Pharmaceuticals上调11亿美元私人债务发行价格
2026-08-27 16:28
- Jazz Pharmaceuticals (JAZZ) announced the pricing of $1.1B aggregate principal amount of 1.875% exchangeable senior notes due 2032.
- The offering was upsized from the previously announced offering size of $1B aggregate principal amount of notes.
- The notes will accrue interest payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2027, at a rate of 1.875% per year. The notes will mature on September 15, 2032, unless earlier exchanged, redeemed or repurchased.
- The issuer also granted the initial purchasers of the notes the right to purchase, exercisable within a 13-day period from, and including the initial issue date of the notes, up to an additional $150M aggregate principal amount of notes.
- The sale of the notes is expected to close on August 31, 2026. The stock closed down 4% on Wedneday.
More on Jazz Pharmaceuticals
- Jazz Pharmaceuticals plc (JAZZ) Discusses FDA Approval and Commercial Launch of ZIIHERA for First-Line HER2-Positive GEA - Slideshow
- Jazz Pharmaceuticals plc (JAZZ) Discusses FDA Approval and Commercial Launch of ZIIHERA for First-Line HER2-Positive GEA Transcript
- Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout
- Jazz Pharmaceuticals announces private offering of $1B of exchangeable senior notes due 2032 and concurrent share repurchases
- Jazz wins FDA nod for cancer therapy developed with BeOne, Zymeworks
推薦文章
華盛早報 | 美聯儲鷹派加息「嚇壞」美股！沃什再度拒絕給出點陣圖；OpenAI提議設立AI安全報告機制；NEBIUS上調英偉達GPU租賃價
今夜加息概率升破92%！全球風暴即將來襲？覆盤近三輪加息周期，這次會走2015還是2022年劇本？
5%美債收益率風暴來襲！再融資炸彈倒計時開啟，誰會是第一個犧牲品？
美參議院加密市場結構法案程序性投票未獲通過 兩黨談判破裂致立法進程受阻
利率決議前夕黃金「搶跑」！美聯儲兩難困境正被看穿：加息是利空出盡，不加息金價衝5000？
扎克伯格稱更青睞依靠評估人員確保AI安全 而非放緩發展
攜程2026Q2淨利潤同比下降，受處罰費用影響，錄得淨虧損24億元！
加密貨幣法案折戟美國參議院！比特幣、以太幣跌至6月來最低
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
